N. Khan, “Prospective Evaluation of Atrial Fibrillation Risk in Type 2 Diabetes Comparing SGLT-2 Inhibitors and DPP-4 Inhibitors”, IJBR, vol. 3, no. 3, pp. 69–75, Mar. 2025, doi: 10.70749/ijbr.v3i3.797.